FDA Issues CBD Warning Letters
go.ncsu.edu/readext?644294
en Español / em Português
El inglés es el idioma de control de esta página. En la medida en que haya algún conflicto entre la traducción al inglés y la traducción, el inglés prevalece.
Al hacer clic en el enlace de traducción se activa un servicio de traducción gratuito para convertir la página al español. Al igual que con cualquier traducción por Internet, la conversión no es sensible al contexto y puede que no traduzca el texto en su significado original. NC State Extension no garantiza la exactitud del texto traducido. Por favor, tenga en cuenta que algunas aplicaciones y/o servicios pueden no funcionar como se espera cuando se traducen.
Português
Inglês é o idioma de controle desta página. Na medida que haja algum conflito entre o texto original em Inglês e a tradução, o Inglês prevalece.
Ao clicar no link de tradução, um serviço gratuito de tradução será ativado para converter a página para o Português. Como em qualquer tradução pela internet, a conversão não é sensivel ao contexto e pode não ocorrer a tradução para o significado orginal. O serviço de Extensão da Carolina do Norte (NC State Extension) não garante a exatidão do texto traduzido. Por favor, observe que algumas funções ou serviços podem não funcionar como esperado após a tradução.
English
English is the controlling language of this page. To the extent there is any conflict between the English text and the translation, English controls.
Clicking on the translation link activates a free translation service to convert the page to Spanish. As with any Internet translation, the conversion is not context-sensitive and may not translate the text to its original meaning. NC State Extension does not guarantee the accuracy of the translated text. Please note that some applications and/or services may not function as expected when translated.
Collapse ▲
The U.S. Food & Drug Administration (FDA) recently released warning letters to 15 companies in late November for selling products containing cannabidiol (CBD) compounds. CBD has not been evaluated by the FDA for safety, and it is not considered a Generally Recognized as Safe (GRAS) additive for human or animal food.
According to the FDA: “Under the FD&C Act, any product intended to treat a disease or otherwise have a therapeutic or medical use, and any product (other than a food) that is intended to affect the structure or function of the body of humans or animals, is a drug. The FDA has not approved any CBD products other than one prescription human drug product to treat rare, severe forms of epilepsy. There is very limited information for other marketed CBD products, which likely differ in composition from the FDA-approved product and have not been evaluated for potential adverse effects on the body.”
One of the FDA concerns is the use of CBD or cannabis-derived compounds in animal food for food-producing animals. The safety of human food products from animals that consume CBD is a concern because there is little data on safe CBD residue levels for humans. Additionally, CBD remains to be evaluated for safety based on different species, breeds or classes.
Get more information on CBD in animal food:
FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
FDA is Committed to Sound, Science-based Policy on CBD
If you have questions about ingredient approvals or CBD in animal food, please contact Marissa Herchler.